Connor Clark & Lunn Investment Management Ltd. Buys 92,797 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in Kiniksa Pharmaceuticals by 30.2% in Q1, now owning 399,743 shares valued at approximately $8.88 million.
• Kiniksa Pharmaceuticals' stock opened at $32.74 and has a market capitalization of $2.43 billion, reflecting a 1.8% increase in share price.
• Analysts have a consensus rating of "Buy" for Kiniksa Pharmaceuticals with target prices ranging up to $54.00, indicating strong investor interest and confidence in the stock's performance.

Connor Clark & Lunn Investment Management Ltd. lifted its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 30.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,743 shares of the company's stock after buying an additional 92,797 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.55% of Kiniksa Pharmaceuticals International worth $8,878,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after buying an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $42,000. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA traded up $0.10 during trading hours on Friday, hitting $33.38. 588,646 shares of the company were exchanged, compared to its average volume of 720,060. The company has a market capitalization of $2.47 billion, a PE ratio of 834.71 and a beta of 0.14. The firm has a fifty day simple moving average of $29.36 and a 200-day simple moving average of $25.01. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $33.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 138,614 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the completion of the sale, the chief operating officer owned 49,915 shares of the company's stock, valued at $1,657,178. This trade represents a 73.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $32.89, for a total value of $621,259.21. Following the sale, the chief financial officer owned 27,009 shares of the company's stock, valued at approximately $888,326.01. This represents a 41.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 675,486 shares of company stock valued at $21,044,633 over the last quarter. 53.48% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KNSA. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Wells Fargo & Company raised their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.